Aldridge, RW; Iglesias, D; Caceres, CF; Miranda, JJ (2009) Determining a cost effective intervention response to HIV/AIDS in Peru. Bmc Public Health, 9. ISSN 1471-2458

Downloaded from: http://researchonline.lshtm.ac.uk/4538/

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: Creative Commons Attribution http://creativecommons.org/licenses/by/2.5/
Research article

Determining a cost effective intervention response to HIV/AIDS in Peru

Robert W Aldridge*1, David Iglesias2, Carlos F Cáceres3,4 and J Jaime Miranda5,6

Address: 1Department of Epidemiology & Public Health, University College London, London, UK, 2Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru, 3School of Public Health, Universidad Peruana Cayetano Heredia, Lima, Peru, 4Institute of Studies in Health, Sexuality and Human Development, Lima, Peru, 5Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK and 6School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru

Email: Robert W Aldridge* - rob.aldridge@gmail.com; David Iglesias - daviglesias@gmail.com; Carlos F Cáceres - carlos.caceres@upch.pe; J Jaime Miranda - jaime.miranda@lshtm.ac.uk

* Corresponding author

Abstract

Background: The HIV epidemic in Peru is still regarded as concentrated - sentinel surveillance data shows greatest rates of infection in men who have sex with men, while much lower rates are found in female sex workers and still lower in the general population. Without an appropriate set of preventive interventions, continuing infections could present a challenge to the sustainability of the present programme of universal access to treatment. Determining how specific prevention and care strategies would impact on the health of Peruvians should be key in reshaping the national response.

Methods: HIV/AIDS prevalence levels for risk groups with sufficient sentinel survey data were estimated. Unit costs were calculated for a series of interventions against HIV/AIDS which were subsequently inputted into a model to assess their ability to reduce infection transmission rates. Interventions included: mass media, voluntary counselling and testing; peer counselling for female sex workers; peer counselling for men who have sex with men; peer education of youth in-school; condom provision; STI treatment; prevention of mother to child transmission; and highly active antiretroviral therapy. Impact was assessed by the ability to reduce rates of transmission and quantified in terms of cost per DALY averted.

Results: Results of the analysis show that in Peru, the highest levels of HIV prevalence are found in men who have sex with men. Cost effectiveness varied greatly between interventions ranging from peer education of female commercial sex workers at $US 55 up to $US 5,928 (per DALY averted) for prevention of mother to child transmission.

Conclusion: The results of this work add evidence-based clarity as to which interventions warrant greatest consideration when planning an intervention response to HIV in Peru. Cost effectiveness analysis provides a necessary element of transparency when facing choices about priority setting, particularly when the country plans to amplify its response through new interventions partly funded by the GFATM.

Published: 18 September 2009

BMC Public Health 2009, 9:352 doi:10.1186/1471-2458-9-352

Received: 11 November 2008

Accepted: 18 September 2009

This article is available from: http://www.biomedcentral.com/1471-2458/9/352

© 2009 Aldridge et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background
Patterns of the human immunodeficiency virus (HIV) vary across countries and regions, and the most vulnerable populations are not necessarily equivalent internationally or across continents. Recent data from the Peruvian Ministry of Health states that as of 31 December 2007, 30,389 cases of HIV and 20,610 cases of acquired immunodeficiency syndrome (AIDS) had been reported in the general population since 1983[1,2]. The Peruvian HIV epidemic is predominantly concentrated in men who have sex with men (MSM), with lower rates found in female sex workers (FSW) and lower still in the general population[3,4], and virtually no cases are reported amongst injecting drug users since such practice is rare in Peru.

In 2001 the United Nations (UN) adopted a set of commitments aimed at the prevention and treatment of HIV/AIDS. Prior to implementation, analysis was performed to determine the necessary resources and likely cost implications that this would entail[5]. In 2002, Stover et al[6] attempted to determine the effect of expanding such preventative interventions on global transmission rates. Their findings suggested that a further 29 million new infections could be prevented worldwide by 2010[5].

Here we attempt to evaluate potential HIV prevention strategies in Peru in terms of their ability to reduce Disability Adjusted Life Years (DALYS) individually and in combination. Whilst the epidemic in this country seemed to have stabilized at least a decade ago, and antiretroviral treatment (ART) has been offered free of charge by the Ministry of Health since 2004, insufficient prevention efforts might increase the cost of treatment and affect its sustainability [1,7]. Moreover, a number of new prevention projects are currently being funded by the Global Fund for AIDS, Tuberculosis and Malaria (GFATM) in Peru and other countries with similar epidemics. New cost-effectiveness data from these projects can therefore be used together with monitoring and evaluation to, if necessary, revise planned interventions to ensure that new resources are used in the most effective manner.

Methods
Baseline prevalence levels of HIV/AIDS in Peru
HIV prevalence levels in Peru were estimated using the Estimation and Projection Package (EPP), following the methodology as used by the Joint United Nations Programme on HIV/AIDS and the World Health Organisation (WHO) in projecting the WHO/UNAIDS country estimates [8-10]. Sentinel surveillance data, as used in their country estimates [11,12], was incorporated in our calculations of prevalence. The three main groups with sufficient available sentinel data were: MSM, FSW and pregnant women - the size of these groups and length of time they are assumed to remain in these groups are presented in Table 1. Sentinel data was available for the period 1985 to 2002 and for the MSM, FSW and pregnant women groups there were a total of 21, 14 and 67 published sentinel survey values used in the analysis[11,12]. National data was then estimated by applying the concentrated epidemic curves for the individual risk groups countrywide. Baseline projections were calculated on the assumption that behavioural changes do not occur in the future. Full details of the methodology followed for this work have been published elsewhere[10,13,14].

The GOALS model
The GOALS model has been used in previous global and regional HIV analyses to assess the ability of a variety of interventions against HIV/AIDS to reduce rates of transmission in these regions [6,13]. The GOALS model is a deterministic model that uses data in three main areas to project HIV prevalence and incidence: demography; sexual behaviour; and HIV and sexually transmitted infection (STI) rates. GOALS considers four different risk groups, the exact definition of which is specified by the user. For the purposes of this analysis the groups were defined as: MSM, FSW and their clients, men and women with multiple sexual partners, and men and women in steady sexual relationships.

Initial parameter ranges for behavioural and biological inputs were specified based on a review of the available literature (see Tables 2 and 3 for full details). Ten thou-

| Population          | Population size (15 years +) | Details of estimation                                      |
|---------------------|------------------------------|------------------------------------------------------------|
| MSM                 | 620,978*                     | Based on 2005 estimate [23]                                |
| FSW                 | 25,500†                      | 2002 figure (average) based national aids programme report to UNAIDS[49] |
| Pregnant women      | 587,000‡                     | 2005 Figures based on births per year[50]                  |
| Remaining population| 26,040,522                   | 2005 Figures from UN Population data base and calculated by subtracting populations from [50] |

*MSM remain in this group for lifetime
† FSWs are estimated to remain in this population for an average of 5 years and return to remaining population afterwards
‡ Pregnant women remain in population for one year and return to remaining population afterwards
and simulations of the GOALS model were then computed using @RISK software[15] to perform iterations using the Monte Carlo simulation method. Each iteration of the model sampled parameter values randomly from the uniform distributions defined by the ranges detailed in Tables 2 and 3. For each iteration, projected HIV prevalence levels for the period 1999 to 2004 were compared to those calculated by the baseline EPP analysis described in the last section which predicted baseline prevalence levels for HIV in Peru based on sentinel survey data. The set of behavioural and biological inputs within the GOALS model that minimized the deviation of HIV prevalence from the projected EPP analysis across the period 1999 to 2004 was then identified as the best-fit set of values to be used within the subsequent calculations and analysis of intervention effects.

### Table 2: Behavioural parameters used in the GOALS model: Ranges and best fit values.

| Input | Min | Max | Best fit | Source |
|-------|-----|-----|----------|--------|
| Percent of men 15-49 that are sexually active | 88.0 | 95.3 | 94.0 | [39,51] |
| Percent of women 15-49 that are sexually active | 74.8 | 95.5 | 91.0 | [39,51] |
| Sexually active 15-19 as % of 15-49 | 54.2 | 76.8 | 67.0 | [51] |
| MSM | | | | |
| Input | Min | Max | Best fit | Source |
| Percent of men in risk group | 0.0 | 15.0 | 3.2 | [23,39,46] |
| coital frequency (acts per year) | 30 | 70 | 35.7 | [13] |
| number of partners per year | 1 | 6 | 1.2 | [39] |
| Condom usage (percentage of acts) | 24.3 | 55.6 | 53.6 | [46] |
| High risk men | | | | |
| Input | Min | Max | Best fit | Source |
| Percent of men in risk group | 4.0 | 36.0 | 4.4 | [39,51] |
| coital frequency (acts per year) | 2 | 70 | 10.0 | [13,47] |
| number of partners per year | 2 | 89 | 2.5 | [13] |
| Condom usage (percentage of acts) | 59.6 | 95.8 | 93.9 | [7] |
| Medium risk men | | | | |
| Input | Min | Max | Best fit | Source |
| Percent of men in risk group category | 5.0 | 16.0 | 12.4 | [13,52] |
| coital frequency (acts per year) | 30 | 70 | 31.0 | [13] |
| number of partners per year | 2 | 5 | 2.2 | † |
| Condom usage (percentage of acts) | 7.5 | 36.6 | 19.2 | [51] |
| Low risk men | | | | |
| Input | Min | Max | Best fit | Source |
| Percent of men in risk group category | * | * | * | * |
| coital frequency (acts per year) | 30 | 70 | 38.9 | [13] |
| number of partners per year | 1 | 2 | 1.1 | † |
| Condom usage (percentage of acts) | 0.0 | 28.9 | 23.8 | [51] |

Partners per year Women (percentage of total female population aged 15-49 in risk group)

| Input | Min | Max | Best fit | Source |
|-------|-----|-----|----------|--------|
| High risk (< 0.0%) | 500 | 1200 | 559.5 | [13,52] |
| Medium Risk (18.5%) | 1 | 3 | 1.5 | † |
| Low risk (81.5%) | 1 | 2 | 1.0 | † |

*Determined as remainder of MSM, High and Medium risk groups
† Number of partners per year for the low and medium risk groups provides the basis of stratification by which the risk group is defined.

### Calculating the costs of interventions

Unit costs for prevention interventions (per person reached) were calculated using a methodology published jointly by Asian Development Bank, UNAIDS, Futures Group International and Ease International[16]. The outputs of this software were specifically designed to work with the GOALS model and have been implemented previously in Indonesia[16]. Unit costs applied in estimating final values based upon on either: published Peruvian data; field experience of local experts working at local NGOs the authors held discussions with; or finally from direct programme experience of the Peruvian-based authors. Assumptions about personnel-to-participant ratios presented in the supplementary material are based upon values used in prior analysis[16] and expert local opinion [see Additional file 1]. Detailed unit costs used to
calculate the cost per person reached for each intervention are presented in the supplementary material accompanying this article [see Additional file 1].

**Modelling HIV Interventions effects in Peru**

Interventions individually against HIV, and then in combination, were assessed against a "no intervention" scenario, with the outcome measures of cost per infection averted and DALYS [17] used to assess effectiveness. The "no intervention" scenario was calculated by setting the coverage of all other interventions other than those being assessed, including condom usage, to zero. A number of interventions are available in GOALS, those chosen for inclusion in this study were:

- Mass media - media campaigns targeted at the general population. Costing is based on an average campaign price with four promotions per year - newspaper inserts delivered to 7% of the population, 52 TV emissions and 180 radio transmissions - reaching half of the adult population.
- Voluntary counselling and testing - the number of tests required is equal to twice the number of people infected with HIV. It was assumed that people will request a new test every five years.
- Peer counselling and treatment of sexually transmitted infections for female sex workers- the need is assumed to include all sex workers. Peer educators are
trained by health professionals and provide condoms during counselling sessions.

- Peer counselling and treatment of sexually transmitted infections for MSM - outreach programmes similar to peer counselling for sex workers - condoms are provided during counselling sessions.

- Youth - includes children in the formal education system aged between 10 and 18. Sessions occur during normal school activities and are run by teachers who have undergone specific training.

- Condoms - public sector condom distribution, male type only. Demand is calculated by sexually active population, proportion of sexually active population in high and medium risk groups, number of partners, and number of contacts per partner in each risk group. Condoms are included as part of other interventions including all peer education interventions and STI treatment.

- STI treatment - Available to anyone requesting this activity. Prevalence rates are specified for each risk group in Table 3. Activity includes costs of treatment, counselling and condom provision. Drugs costs based on an average for treatment of urethral and vaginal discharge, genital ulcers and pelvic inflammatory disease.

- Prevention of mother to child transmission - includes counselling pre and post test, and nevirapine for mother and child if accepted.

- Highly active antiretroviral therapy - based on the three alternative treatment regimes proposed in a report addressing the implementation of an antiretroviral programme for Peru [1]. The basic programme includes: ARVS, Monitoring (CD4 + Viral Load). Intermediate programme is comprised of: Basic programme activities and imaging tests, additional lab monitoring, administrative costs. The comprehensive programme consists of: Intermediate programme activities and treatment of opportunistic infections.

The interventions outlined above influence rates of HIV transmission in GOALS by altering behavioural factors including: rates of condom use; treatment of STIs; number of sexual partners and age at first sex is supplied in the supplementary material for this article [see Additional file 1].

DALYS averted were calculated using the number of infections averted per year and translating this into a new figure of years of life lost (YLLs) due to premature death and equivalent 'healthy' years lost due to disability (YLDs). The full calculation of the DALYs uses the methodology described by Fox-Rushby et al [20]. Spectrum was used to project HIV incidence and deaths in 5 year intervals (ages 15-80+). Survivorship with HAART was calculated using recently published Peruvian data [21].

**Uncertainty Analysis**

Many of the behavioural and prevalence values used in the GOALS model have a level of uncertainty associated with them and in order to analyse the effects these have on the results, two sets of uncertainty analysis were carried out. Firstly, the effectiveness of interventions was recalculated using the values of low, average and high intervention effectiveness as included within the GOALS model [see Additional file 1]. Additionally, 10 separate computations of the model were run using randomly chosen values for the behavioural and biological parameters that created HIV prevalence rates which did not deviate by greater than 50% from the baseline predictions. Only biological parameters listed in table 3 were included within this analysis, those in the supplementary materials [see Additional file 1 - Stable 9] accompanying this report were not. Finally, a separate calculation of baseline prevalence rates was carried out using a prior version of EPP [22] for comparison of results.

**Ethics**

The study protocol was reviewed and approved by Universidad Peruana Cayetano Heredia's Independent Review Board.

**Results**

**Estimated prevalence levels of HIV in Peru - baseline projection data**

The three main groups for which there were sufficient data available to make estimates of prevalence were: female sex workers, MSM and pregnant women. For 2008, the total number of people living with HIV was estimated as 63,795, a prevalence of 0.32%. Prevalence levels for MSM, FSW and pregnant women were 8.93%, 2.1%, and 0.15% respectively.

**Costs per person reached for prevention and treatment of HIV/AIDS**

Table 4 summarises the unit costs per person reached by the interventions for prevention and treatment activities. Estimates for prevention activities were based on target group sizes of 1000 people and therefore economies of
Blood safety, condom distribution, and peer education of both, youth in school and MSM, provided the greatest rates of total infections averted. However, it must be noted that these values of total infections averted should not be compared against current epidemiological estimates as they do not take into account existing interventional impacts on condom usage, treatment of STIs and reduction in high risk behaviour which were set to zero for the purposes of this part of the analysis.

Figure 1 shows the incremental benefits of each additional intervention as it is added to the package of interventions. The order in which interventions were added is based entirely upon the average cost effectiveness ratio ($/DALY averted) as detailed in Table 5.

**Sensitivity of the analysis to changes in intervention impacts**

A series of sensitivity analyses were carried out to determine the impact of various assumptions within the model on the relative rankings of the cost effectiveness of each intervention. The effectiveness of interventions was recalculated using the values of low, average and high intervention effectiveness as included with the GOALS model. The effectiveness of interventions had impacts on the following factors: rates of condom use; treatment of STIs; number of sexual partners and age at first sex. Increasing the interventional effectiveness to a higher level had very little impact on the rankings apart from voluntary counselling and testing moved ahead of blood safety. Reducing the rankings to a lower level had more of an impact on the ranking of interventions: blood safety became the most cost effective, followed by peer education of youth and then voluntary counselling and testing.

In addition to this, 10 separate computations of the model were run using randomly chosen values for the behavioural and biological parameters that created HIV prevalence rates which did not deviate by greater than 50% from the baseline predictions. This analysis showed that for total infections averted over the five year period youth in-school, condoms and FSW showed the greatest absolute range of values, and blood safety, mass media and MSM interventions varied the least. In terms of rankings of the interventions based upon average cost effectiveness ratio ($/DALY averted) the model remained fairly stable. FSW and MSM both varied by only one place, the most variation across the rankings was shown by youth education (varying from first to fifth place) and condoms (varying from fourth to seventh place).

A separate calculation of baseline prevalence rates was carried out using a prior version of EPP[22] for comparison. Main differences in the modelling of data between the two versions were that the newer version of the software

---

**Table 4: Unit costs per person reached by intervention in 2008 $US.**

| Intervention                  | Cost per person reached |
|-------------------------------|-------------------------|
| STI treatment                 | $US 3.7                 |
| Cost per STI case treated     |                         |
| Youth                         | $US 8.0                 |
| Cost per youth reached by peer educator |               |
| Cost per teacher trained      | $US 62.0                |
| Commercial sex worker         | $US 124.0               |
| Cost per sex worker reached   |                         |
| Mass media                    | $US 0.4                 |
| Cost per person reached with mass media |            |
| MSM                           | $US 103.0               |
| Cost per person reached       |                         |
| Voluntary counselling and testing | $US 40.0               |
| Total costs per client        |                         |
| Prevention of mother to child transmission | $US 23.2               |
| Cost per mother and child treated |                         |
| Antiretroviral programmes*    | $US 3379                |
| Basic†                        |                         |
| Intermediate‡                 | $US 3788                |
| Comprehensive§                | $US 3792                |

Further details of the individual unit costs and assumptions made for each intervention are provided in the supplementary materials that accompany the manuscript [see Additional file 1].

*Costing for highly active antiretroviral therapy (HAART) were computed based on local protocols and prior analysis[1].
† Antiretrovirals, Monitoring (CD4 + Viral Load)
‡ Basic programme + Imaging tests, additional lab monitoring, administrative costs
§ Intermediate programme + treatment of opportunistic infections

scale were ignored. Personnel and peer educator costs formed the highest proportion of most prevention strategies and final values are therefore extremely sensitive to assumptions about these values. Unit costs varied from $US 8 per youth reached by peer educator, up to $US 124 per commercial sex worker reached. HAART costs varied from $US 3379 for a basic programme to $US 3792 for a comprehensive package.

**Projections of the effects of interventions**

Tables 2 and 3 detail what was calculated as the best fit set of biological and behavioural parameters for the baseline prevalence estimates in GOALS. Table 5 shows the results for the number of infections averted and the cost effectiveness of these interventions expressed in terms of cost per infection averted and cost per DALY averted. The results suggest that if cost effectiveness were the only consideration when choosing which interventions to implement first then peer education of female sex workers, blood safety, peer education of youth in school and voluntary counselling and testing would be ranked ahead of others.
allows more accurate initial estimates of prevalence for individual risk groups and allows reassignment of populations between risks groups which particularly impacts the FSWs modelling in this work. Results of this analysis showed that for 2008, the total number of people living with HIV was estimated as 62,910; 43,799 of which were male, and 19,112 female. Prevalence levels for MSM, commercial sex workers and pregnant women were 9.0%, 0.8%, and 0.2%, respectively. The expansion pathway resulting from this analysis showed, blood safety, peer education of sex workers, peer education of youth in school and voluntary counselling and testing to be the most cost effective order.

**Table 5: Interventions against HIV/AIDS and their associated coverage levels, total costs, yearly costs, yearly infections averted, yearly DALYS averted and sorted by average cost effectiveness**

| Intervention   | Coverage level (%) | Total costs ($ Millions) 2008-2013 | Yearly costs ($ Millions) | Total infections averted (2008-2013) | Yearly infections averted | Yearly DALYS averted | Average cost effectiveness - $/DALY averted (range*) |
|----------------|--------------------|-------------------------------------|---------------------------|-------------------------------------|--------------------------|--------------------|-----------------------------------------------|
| FSW            | 50                 | 0.6                                 | 0.1                       | 1,970                               | 394                      | 10,118             | 55 (2 - 124)                                   |
| FSW            | 95                 | 1.0                                 | 0.2                       | 3,730                               | 746                      | 19,157             | 55 (1 - 105)                                   |
| FSW            | 80                 | 0.9                                 | 0.1                       | 3,130                               | 626                      | 16,076             | 55 (2 - 116)                                   |
| Blood safety   | 50                 | 5.3                                 | 0.9                       | 13,050                              | 2,610                    | 67,025             | 79 (41 - 79)                                   |
| Blood safety   | 80                 | 8.5                                 | 1.4                       | 20,570                              | 4,114                    | 105,648            | 80 (43 - 80)                                   |
| Blood safety   | 95                 | 10.1                                | 1.7                       | 24,260                              | 4,852                    | 124,599            | 81 (43 - 91)                                   |
| VCT            | 95                 | 8.2                                 | 1.4                       | 13,870                              | 2,774                    | 71,236             | 116 (18 - 116)                                 |
| VCT            | 50                 | 4.4                                 | 0.7                       | 7,300                               | 1,460                    | 37,493             | 118 (18 - 118)                                 |
| VCT            | 80                 | 7.1                                 | 1.2                       | 11,670                              | 2,334                    | 59,937             | 118 (18 - 118)                                 |
| Youth: in-school | 50          | 13.7                                | 2.3                       | 21,760                              | 4,352                    | 131,126            | 104 (12 - 177)                                 |
| Youth: in-school | 80         | 22.0                                | 3.7                       | 22,760                              | 4,552                    | 137,152            | 161 (19 - 270)                                 |
| Youth: in-school | 95         | 26.2                                | 4.4                       | 23,020                              | 4,604                    | 138,719            | 189 (12 - 630)                                 |
| mass media     | 50                 | 11.3                                | 1.9                       | 8,930                               | 1,786                    | 45,864             | 246 (89 - 253)                                 |
| Condoms        | 95                 | 61.0                                | 10.2                      | 23,740                              | 4,748                    | 121,929            | 500 (64 - 500)                                 |
| Condoms        | 80                 | 51.3                                | 8.6                       | 19,890                              | 3,978                    | 102,155            | 503 (62 - 503)                                 |
| Condoms        | 50                 | 32.1                                | 5.3                       | 12,430                              | 2,486                    | 63,840             | 503 (58 - 503)                                 |
| STI treatment  | 50                 | 25.1                                | 4.2                       | 6,600                               | 1,320                    | 33,898             | 739                                           |
| STI treatment  | 80                 | 40.1                                | 6.7                       | 10,290                              | 2,058                    | 52,849             | 759                                           |
| STI treatment  | 95                 | 47.6                                | 7.9                       | 12,080                              | 2,416                    | 62,043             | 767                                           |
| MSM            | 50                 | 75.0                                | 12.5                      | 11,090                              | 2,218                    | 56,958             | 1,317                                         |
| MSM            | 80                 | 120.0                               | 20.0                      | 17,570                              | 3,514                    | 90,240             | 1,330                                         |
| MSM            | 95                 | 142.5                               | 23.8                      | 20,770                              | 4,154                    | 106,675            | 1,336                                         |
| HAART          | Comprehensive      | 95                                  | 37.7                      | 6.3                                  | -                       | -                  | 18917                                         |
| HAART          | Intermediate       | 95                                  | 37.7                      | 6.3                                  | -                       | -                  | 16412                                         |
| HAART          | Basic              | 95                                  | 33.6                      | 5.6                                  | -                       | -                  | 13999                                         |
| HAART          | PMTCT              | 80                                  | 246.4                     | 41.1                                 | 10,460                   | 2092               | 41,357                                         |

*Ranges based upon sensitivity analysis whereby the model was run using randomly generated values for the behavioural and biological parameters which were varied so that HIV prevalence rates did not deviate by greater than 50% from the baseline predictions.*

**Discussion**

The primary aim of this analysis was to determine how an intervention response to HIV could be most cost effectively implemented in Peru. This analysis provides estimates of historical and future levels of HIV based on the best available data and using methods currently recommended by UNAIDS in producing country estimates. Using these baseline prevalence estimates, an evaluation
of the cost effectiveness of a series of separate interventions aimed at reducing the levels of HIV transmission for the period 2008 - 2013 has been carried out.

Estimates for the number of people living with HIV in Peru vary widely depending on the source, and range from 20,000 to 144,000 [23]. Levels predicted by this work for 2007 were 62,450 which are between these limits and in the lower range of those predicted by UNAIDS (57,000 to 97,000 people living with HIV/AIDS for 2007) [24] for the same year.

In 1993 the first global comparison of a large number of interventions against a range of diseases determined that interventions costing less than US$1000 per DALY averted were cost-effective [25]. However, a more up to date set of criteria suggested by the Commission on Macroeconomics and Health states that interventions costing less than three times GDP per capita to avert each DALY are cost-effective [26]. Using the second of these two definitions of cost effectiveness, and considering Peru’s GDP per capita was US$7,600 in year 2007 [27], all of the interventions included in this study would be regarded as cost-effective.

The inclusion of HAART within this analysis may be considered controversial. After years of campaigning for access to treatment we are not intending to undermine HIV positive Peruvians their fundamental right to treatment. However, the finding that HAART is one of the more costly interventions will come as no surprise and is consistent with other studies using similar methodologies [13]. Whilst HAART is one of the most expensive options, it remains cost effective by the definitions outlined above and without any doubt should be included in any package against HIV in Peru. Importantly, our estimates of average cost effectiveness ratios (between $US 1995 for a basic programme to $US 2403 for a comprehensive package $/DALY averted) are in a similar range to
those presented in another study that estimated cost effectiveness for antiretroviral therapy for Africa in 2002 as between $US1100 and $US1800[28]. Another study looking at the regions of sub-Saharan Africa and South East Asia found that antiretroviral therapy in these areas was calculated to cost between $Int 542 and $Int 2010 - $Int being a hypothetical currency that have the same purchasing power that the $US has in the United States at any given point[13].

As with any exercise in cost-effectiveness estimation, this analysis is not free from limitations which warrant caution when considering the implications of the results presented. Deciding what interventions to include was determined by three factors: whether the intervention was included in the GOALS model; whether sufficient information was available for its inclusion in the model[19]; and whether an intervention was deemed locally appropriate. The set of interventions chosen as a result of this work may not therefore represent the best case scenario and more appropriate options may exist. It is important to note that of all the studies used in determining the impact of interventions within the GOALS model, only very few of these were actually carried out in Latin America[18,29-37]. Although reproducibility in Latin America should be possible, their impact may vary in comparison to the initially reported studies, which would have an effect on their cost effectiveness when applied in Peru.

The higher risk groups which the interventions in this model are targeted at are presented in this paper as discrete cohorts. However, as many papers in Peru have suggested, this categorisation of people based on certain behaviours or sexual preferences not only excludes certain groups at higher risk, but includes others inappropriately [38-41]. The GOALS model, as it currently stands, does not allow for full mixing between the at risk groups over the analysis period which would differ from reality, as for example, some high risk will move to the low risk group over the time course of the analysis. This lack of sub-categorisation, mixing over time of the groups within the analysis over time, and the associated limitations is acknowledged, however, carrying out the analysis in this way allows a certain amount of comparability across studies by replicating methods and techniques applied elsewhere [5,6,10,13,19,42].

It is suggested that due to levels of uncertainty in the assumptions used in the model, interpretation of results should be based on broad categories of cost effectiveness rather than the absolute levels of infections preventable per intervention. The rankings suggested by this analysis are meant as a guide only and the exact order should not be taken as an absolute, as demonstrated by the sensitivity analysis. The values presented in table 5 should not be compared to current epidemiological estimates as they do not take into account existing interventional impacts on condom usage, treatment of STIs and reduction in high risk behaviour, which were set to zero. As a result, data must be interpreted with caution by policy makers as it does not include interventions which are currently occurring. The necessary information required to make such an assessment of interventions compared to current efforts levels is unfortunately lacking in many areas at present.

Apart from the uncertainties within the analysis, there are other legal and social factors to consider when weighing up the results of this cost effectiveness analysis such as the increasing perception of certain services as rights and social legitimacy. Such factors are even more pertinent for the MSM and FSW interventions where the stigma associated with membership of these groups leads to the avoidance of people assuming the identity of these at risk groups. Although the uncertainty analysis in the study goes some way to addressing infectivity and the clinical stage of HIV/AIDS, practical issues such as these which impact on clinical management of patients, were ignored by this analysis.

The ability of HAART to impact on sexual behaviour and transmissibility was not included in this analysis as this facility is not currently included in the interventional impacts in the GOALS model. Consequently this analysis may underestimate the actual cost effectiveness of this intervention. Precise and reliable estimates regarding the behavioural and biological inputs required for the model were limited and many figures used in the analysis were based on studies of small numbers of subjects. In some areas in particular, such as number of coital acts per year and number of partners per year for some of the risk groups, no data existed resulting in assumptions being made regarding this data. As called for in another article [4] this data should be collected as a matter of priority in order that more accurate analysis is carried out in the near future.

Unit costs calculated by the analysis were substantially influenced by personnel and peer educator costs. Final results are therefore sensitive to assumptions about these values. Values for the unit costs per person reached varied from $US 8 per youth reached up to $US 3792 for a comprehensive HAART programme. These HAART values appeared reasonable when compared with other such calculations (estimated values between $US395 and $US 5400 for various countries in Latin America)[5,43,44] and on the whole represented good value for money.

The expansion pathway, calculated by adding interventions to each other in order of their cost effectiveness, gives an idea of the levels of synergy that occur by having
multiple intervention strategies and the costs associated with such packages of interventions. As with another study[13], the expansion pathway follows an exponential trajectory as the more expensive interventions are added to the overall strategy.

Peer education of sex workers, mass media, treatment of STIs and voluntary counselling and testing were found to be the four most cost effective interventions in a similar analysis based on South East Asia[13] - blood safety was not included in this analysis. The results of this study suggest that peer education of sex workers, blood safety, peer education of youth in school and voluntary counselling and testing would all substantially reduce the burden of HIV/AIDS in Peru and are economically attractive when using the international accepted definitions based on cost per DALY averted. Although the epidemic of HIV in Peru presents a concentrated high-risk group pattern, with MSM presenting the highest concentration of prevalence, blood safety was shown to be a very cost effective measure because of its broad population based effect. It is important to note that since coverage of blood screening is already nearly 100%, the conclusion we suggest is drawn from this result is that the model supports that blood screening should continue because it is so cost-effective, not that more infections could be averted by better blood screening.

STIs within the model are broadly split into non-ulcerative and ulcerative. This simplification assumes that HSV2 (along with syphilis and chancroid with which it is classified) is curable and has a higher rate of transmission than it does in reality, which is noted as a limitation of this particular model by the authors. We also note the current growing consensus that treatment of STIs, especially in generalized epidemics, appears to have a minimal population level effect, and the growing evidence to support male circumcision which is not currently included within the GOALS model[45].

Interventions targeted at MSM consistently performed well in terms of total infections averted, ranking in the top three, however, it did not perform well in terms of cost effectiveness. Much of this lack of performance can be explained by the inability of the model to compute specific sub-populations of MSM - classifying them as a single homogeneous at risk group ignores the reality of varying behavioural and risk characteristics[39,40,46-48]. If interventions were targeted more specifically at these groups then numbers of participants included would be smaller and the interventions would likely to improve significantly in the cost effectiveness rankings. Unusually for a concentrated epidemic, youth education in school has a large impact on the number of infections averted. This appears to be mainly due to sensitivity of the model to interventions on medium risk groups, which although representing a smaller prevalence, represent a large number of sexual acts performed.

Conclusion
This analysis has determined how an intervention response to HIV could be most cost effectively implemented in Peru. HIV prevalence levels over time for various at risks groups were estimated; country-specific unit costs for a set of prevention and treatment interventions were calculated and a potential cost-effective expansion pathway is presented. The results of this work add evidence-based clarity as to which interventions warrant greatest consideration when planning an intervention response to HIV in Peru. Cost effectiveness analysis provides a necessary element of transparency when facing choices about priority setting with limited resources, but is equally important in an era of unprecedented resources for HIV in Peru and many other countries, and should be considered together with criteria regarding social inclusion and the universal right to health. Likewise, new evidence regarding effectiveness of specific interventions is fundamental, as is the design of new structural interventions to alter their social origin (such as those that create vulnerability) rather than its effects.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
RWA reviewed available data and literature, analysed data, and wrote the manuscript. DI and CFC provided data and editorial comments on the manuscript. JIM provided data, guidance on the analysis, and editorial comments on the manuscript. All authors read and approved the final manuscript.

Additional material

Additional file 1
Supplementary material for article: Determining a cost effective intervention response to HIV/AIDS in Peru. This supplementary material contains additional detail of the data used in the analysis and not presented in the main article.
Click here for file [http://www.biomedcentral.com/content-supplementary/1471-2458-9-352-S1.doc]

Acknowledgements
There was no specific funding for this study. R.W.A. was supported by Amulree Bursary, University College London, AH Bygott Undergraduate Scholarship, University of London, Vandervell Foundation, UK. The initial work on this project was carried out whilst R.W.A. was based at Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana
Cayetano Heredia, Lima, Peru. J.J.M. is supported by a Wellcome Trust Research Training Fellowship (GR074833MA). Our special gratitude goes to Dr Daniel Marks and Dr Juan Echevarria for their valuable inputs to an earlier version of this report.

References

1. Ministerio de Salud del Peru & Universidad Peruana Cayetano Heredia: Recommendations for the Implementation of an HIV/AIDS Antiretroviral Therapy Program in Peru. Lima: Ministerio de Salud del Peru; 2004.

2. Dirección General de Epidemiología: Situación del VIH-SIDA en el Perú. In Boletín Epidemiológico Mensual Lima; Ministerio de Salud del Peru; 2007.

3. García PJ, Zúñiga R, Anamaría P, Mejía L, Gozzer E, Cotrina A, Cárcamo C, Pacheco C: Plan Estratégico Multisectorial para la Prevención y Control de las ITS y el VIH/SIDA en el Perú. Ministerio de Salud del Peru; 2006.

4. Caceres CF, Mendoza W: Monitoring trends in sexual behaviour and HIV/STIs in Peru: are the data sufficient? Sexually transmitted infections 2004, 80(Suppl 2):i80-84.

5. Stover J, Bertozzi S, Gutierrez JP, Walker N, Stanecki KA, Greener R, Gouws E, Hanks C, Garnett GP, Salomon JA, et al.: The global impact of scaling up HIV/AIDS prevention programs in low- and middle-income countries. Science 2006, 311(5766):1474-1479.

6. Stover J, Walker N, Garnett GP, Salomon JA, Stanecki KA, Ghys PD, Grasly NC, Anderson RM, Schwartlander B: Can we reverse the HIV/AIDS pandemic with an expanded response? Lancet 2002, 360(9326):721-727.

7. Miller GA, Mendoza W, Krone MR, Meza R, Caceres CF, Coates TJ, Klausner JD: Clients of female sex workers in Lima, Peru: a bridge population for sexually transmitted disease/HIV transmission? Sexually transmitted diseases 2004, 31(6):337-342.

8. Ghys PD, Brown T, Garnett GP, Salomon JA, Stanecki KA, Stover J, Walker N: The UNAIDS Estimation and Projection Package: a software package to estimate and project national HIV epidemics. Sexually transmitted infections 2004, 80(Suppl 1):i5-9.

9. Grasly NC, Morgan M, Walker N, Garnett GA, Stanecki KA, Stover J, Brown T, Ghys PD: Uncertainty in estimates of HIV/AIDS: the estimation and application of plausibility bounds. Sexually transmitted infections 2004, 80(Suppl 1):i31-38.

10. Stover J, Walker N, Grasly NC, Marston M: Projecting the demographic impact of AIDS and the number of people in need of treatment: updates to the Spectrum projection package. Sexually transmitted infections 2006, 82(Suppl 3):ii45-50.

11. UNAIDS: Peru - Epidemiological fact sheets on HIV/AIDS and sexually transmitted infections. Geneva: UNAIDS; 2004.

12. UNAIDS: Peru - Epidemiological fact sheets on HIV/AIDS and sexually transmitted infections. Geneva: UNAIDS; 2006.

13. Hagan DR, Balsussen R, Hayashi C, Lauer JA, Saloman JA: Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. BMJ (Clinical research ed) 2005, 331(7530):1431-1437.

14. Weinstein MC, Graham J, Siegel J, Fineberg H: Cost-effectiveness analysis of AIDS prevention programs: concepts, complications, and illustrations. In AIDS, Sexual Behavior, and Intravenous Drug Use Edited by: Turner CF, Miller HG, Moses LE. Washington DC: National Academy Press; 1989:471-491.

15. @RISK Professional. 4.5th edition. New York: Palisade Corporation; 2006.

16. Joint United Nations Programme on HIV/AIDS (UNAIDS), Asian Development Bank (ADB): Costing Guidelines for HIV/AIDS Intervention Strategies. 1st edition. Geneva: UNAIDS, ADB; 2004.

17. Global Program on Evidence for Health Policy: National Burden of Disease Manual, templates for calculation of life tables and DALYs, other resources and reference tables 2nd edition. Geneva: World Health Organization; 2001.

18. Bollinger L, Cooper-Arnold K, Stover J: Where are the gaps? The effects of HIV-prevention interventions on behavioral change. Studies in family planning 2004, 35(1):27-38.

19. Stover JBL, Cooper-Arnold K: Goals Model: For estimating the effects of resource allocation decisions on the achievement of the goals of the HIV/AIDS strategic plan. Glastonbury: The Futures Group International; 2003.

20. Fox-Rushby JA, Hanson K: Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. A health Policy Plan 2001, 16(3):226-331.

21. Lopez de Castilla D, Verdonck K, Otero L, Iglesias J, Luteza J, Gotuzzo E, Seas C: Predictors of CD4+ cell count response and of adverse outcome among HIV-infected patients receiving highly active antiretroviral therapy in a public hospital in Peru. Int J Infect Dis 2008, 12(3):325-331.

22. Estimation and Projection Package. Geneva: UNAIDSWHO; 2005.

23. Cáceres Carlos F, Mendoza Walter, Konda Kelka, Lescano Andrés G: Nuevas evidencias para las politicas y programas de salud en VIH/SIDA e infecciones de transmisión sexual en el Perú: información disponible hasta febrero 2007. Lima: Universidad Peruana Cayetano Heredia; Organización Panamericana de la Salud; 2007-41.

24. UNAIDS: Epidemiological Fact Sheet on HIV and AIDS, Core data on epidemiology and response - Peru. Geneva: UNAIDS; 2008.

25. Jamison DT, Mosley WH, Measham AR, Bobadilla JL: Disease control priorities in developing countries New York: Oxford University Press; 1993.

26. Bloom DE, Canning D, Jamison DT: Health, Wealth, and Welfare. Finance and development 2004, 41:10-15.

27. The world fact book Peru [https://www.cia.gov/library/publications/the-world-factbook/geos/pe.html]. Accessed 25 May 2008.

28. Greese A, Floyd K, Albam A, Guiness L: Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet 2002, 359(9218):1635-1643.

29. Uribe-Zuniga P, Brofman-Pertzovksy M, Ortiz-Aguirre V, Marchetti-Lamagni R, Garcia H, Ruiz-Badillo A: A strategy for HIV/AIDS prevention among sexual workers from Chiaapas, Mexico. International Conference on AIDS 1998 1998, 12:903. (abstract no 43285)

30. Peterson C, Szterenfeld C, Alves AB: Monitoring of condom use by female sex workers in Rio de Janeiro and implications for participatory education in AIDS prevention. Proceedings from the Third USAID HIV/AIDS Prevention Conference, Washington, DC 1995.

31. Hearst N, Lacerda R, Gravasto N, Hudes ES, Stall R: Reducing AIDS risk among port workers in Santos, Brazil. American journal of public health 1999, 89(1):76-78.

32. Levine VC, Revollo R, Kauth Y, Vega J, Tinajaros F, Garnica M, Estensorro M, Lewis JS, Figueras G, Zúritza R, et al.: Decline in sexually transmitted disease prevalence in female Bolivian sex workers: impact of an HIV prevention project. AIDS 1998, 12(14):1899-1906.

33. Pauw J, Ferrie J, Rivera Villegas R, Medrano Martinez J, Gorter A, Egger M: A controlled HIV/AIDS-related health education programme in Managua, Nicaragua. AIDS (London, England) 1999, 13(10):537-544.

34. Altersescu X: NGOs network/work together to reduce HIV transmission among sex workers in the Amazon region. International Conference on AIDS 1998, 12:754.

35. Mota M, R Parker, L Lorenzo, C Pimenta, MEL Fernandes: Sexual behavior and behavior change among men who have sex with men in Brazil, 1989-1994. Proceedings from the Third USAID HIV/AIDS Prevention Conference, Washington, DC 1995.

36. Robles RR, H Colon, CA Marrero, TD Matos, A Munoz: Behavioral outcomes of AIDS community-based intervention for drug users in Puerto Rico. International Conference on AIDS 1994, 10(3):272.

37. Silva SaSAdM: Participative interventions among commercial sex workers in Joao Pessoa-Brazil. International Conference on AIDS 1998 1998, 12:914. (abstract no 43342)

38. Salazar X, Caceres C, Rossasco A, Kegeles S, Maiorana A, Garate M, Coates T: Vulnerability and sexual risks: Vaginismus and vaginists in a low income town in Peru. Cull Health Soc 2005, 7(4):375-387.

39. Clark JL, Caceres CF, Lescano AG, Konda KA, Leon SR, Jones FR, Kegeles S: Where are the gaps? The effects of HIV-prevention interventions on behavioral change. Studies in family planning 2004, 35(1):27-38.

40. Fox-Rushby JA, Hanson K: Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. A health Policy Plan 2001, 16(3):226-331.
41. Johnson KM, Alarcon J, Watts DM, Rodriguez C, Velasquez C, Sanchez J, Lockhart D, Stoner BP, Holmes KK. Sexual networks of pregnant women with and without HIV infection. AIDS 2003, 17(4):605-612.

42. Stover J. Projecting the demographic consequences of adult HIV prevalence trends: the Spectrum Projection Package. Sexually transmitted infections 2004, 80(Suppl 1):i14-18.

43. Nunn AS, Fonsekca EM, Bastos FI, Gruskin S, Salomon JA. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment. PLoS Med 2007, 4(11):e305.

44. McGowan CC, Cahn P, Gotuzzo E, Padgett D, Pape JW, Wolff M, Schechter M, Masys DR. Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme. Int J Epidemiol 2007, 36(5):969-976.

45. Potts M, Halperin DT, Kirby D, Swidler A, Marseille E, Klausner JD, Hearst N, Wamai RG, Kahn JG, Walsh J. Public health. Reassessing HIV prevention. Science 2008, 320(5877):749-750.

46. Sanchez J, Lama JR, Goicochea P, Lucchetti A, Rouillon M, Munayco CV, Suarez L, Montano S, et al. HIV-1, sexually transmitted infections, and sexual behavior trends among men who have sex with men in Lima, Peru. J Acquir Immune Defic Syndr 2007, 44(5):578-585.

47. Sanchez J, Gotuzzo E, Escamilla J, Carrillo C, Phillips IA, Barrios C, Stamm WE, Ashley RL, Kreiss JK, Holmes KK. Gender differences in sexual practices and sexually transmitted infections among adults in Lima, Peru. American journal of public health 1996, 86(8):1098-1107.

48. Caceres CF, Konda K, Segura ER, Lyerla R. Epidemiology of male same-sex behaviour and associated sexual health indicators in low- and middle-income countries: 2003-2007 estimates. Sexually transmitted infections 2008, 84(Suppl 1):i49-i56.

49. UNAIDS: Best Practice Collection: Sex work and HIV/AIDS. Geneva: UNAIDS; 2002.

50. Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat: World Population Prospects: The 2006 Revision. New York: United Nations; 2006.

51. Demographic and Health Surveys. United States Agency for International Development & Macro International Inc [http://www.measuredhs.com]. Accessed 26 April 2008.

52. Paris M, Gotuzzo E, Gozyuet G, Aramburu J, Caceres CF, Castellano T, Jordan NN, Vermund SH, Hook EW 3rd. Prevalence of gono-coccal and chlamydial infections in commercial sex workers in a Peruvian Amazon city. Sexually transmitted diseases 1999, 26(2):103-107.

53. Caceres CF, Salazar X, Rossasco A, Mendoza W, Leon S, Sandoval C, Pajuelo J, Klausner J, Maiorana A, Kegeles S, et al. Where the Needs are: Identifying those at higher risk for HIV to implement a prevention trial in lower-income S2 communities in Peru: Implications for public health programming. XV International AIDS Conference. Bangkok, Thailand 2004. Abstract MoPeC3595

54. Clark JL, Konda KA, Munacyo CV, Munayco CV, Leon SR, Pajuelo J, Suarez Ognio L, Klausner JD, Coates TJ, et al. Prevalence of HIV, Herpes Simplex Virus-2, and Syphilis in male sex partners of pregnant women in Peru. BMC Public Health 2008, 8(1):65.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2458/9/352/prepub

Publish with BioMed Central and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:
- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp